FindTrial
Sign In

GnP

DRUG5 trials

Sponsors

Kochi University, Alterome Therapeutics, Inc., West China Hospital, Immuneering Corporation, Gustave Roussy, Cancer Campus, Grand Paris

Conditions

Advanced Solid TumorsCRC (Colorectal Cancer)CancerECOG Performance Status Score of 0 or 1NSCLC (Non-small Cell Lung Cancer)Non MetastaticPDACPDAC - Pancreatic Ductal Adenocarcinoma

Phase 1

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RecruitingNCT06835569
Alterome Therapeutics, Inc.Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer) +2
Start: 2025-03-05End: 2029-08-01Target: 448Updated: 2026-06-10

Phase 2

Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
RecruitingNCT05268692
Kochi UniversityPancreatic Adenocarcinoma
Start: 2019-01-01End: 2030-12-31Target: 500Updated: 2022-03-07
A Phase II, Plateform Study, Open-label, Evaluating the Efficacy and Safety of Neoadjuvant Treatment in Patients With Surgically Resecable Pancreatic Adenocarcinoma.
Not yet recruitingNCT07808567
Gustave Roussy, Cancer Campus, Grand ParisPancreatic Adenocarcinoma Resectable, Non Metastatic, ECOG Performance Status Score of 0 or 1
Start: 2027-01-01End: 2032-01-01Target: 42Updated: 2026-09-09

Phase 3

A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)
Not yet recruitingNCT07336953
West China HospitalPDAC - Pancreatic Ductal Adenocarcinoma
Start: 2026-02-28End: 2028-07-31Target: 198Updated: 2026-01-13
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
RecruitingNCT07562152
Immuneering CorporationPancreatic Cancer, Pancreatic Cancer Metastatic, PDAC +5
Start: 2026-06-05End: 2029-02-01Target: 510Updated: 2026-09-08